查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1760498

2025年心臟药物全球市场报告

Cardiotonic Agents Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年，正性肌力药物市场规模将快速成长。至2029年，该市场规模将成长至50.6亿美元，复合年增长率为12.6%。预测期内的成长可归因于心血管死亡率的上升、以强化正性肌力药物为重点的临床试验的增多、心血管药物研发领域公私合作的加强、与心臟併发症相关的住院人数的增加，以及对个人化心血管医疗需求的不断增长。预测期内的主要趋势包括基于胜肽的研发、双机制药物的创造、药物基因组学的整合、注射剂型的创新以及联合治疗的进步。

心血管疾病盛行率的不断上升预计将在未来几年推动正性肌力药物市场的成长。心血管疾病 (CVD) 包括一组影响心臟和血管的疾病，例如冠状动脉疾病、心臟衰竭、心律不整和中风。这种增长主要是由于不健康的饮食中饱和脂肪酸和反式脂肪酸、盐和糖含量高，导致肥胖、高血压和胆固醇水平升高。正性肌力药物透过提高心肌收缩的效率和力量来改善血液循环并缓解各种心血管疾病的症状。例如，2023 年 12 月，澳洲政府机构澳洲健康与福利研究所报告称，医生认证的因心臟疾病(CHD) 死亡的人数从 2021 年的 14,100 人增加到 2022 年的 14,900 人。因此，心血管疾病盛行率的上升促进了正性肌力药物市场的成长。

强心剂市场主要企业正在开发创新产品，例如旨在改善急性心臟衰竭和心源性休克中心臟功能的短期强心剂。短期强心剂用于暂时增加心臟收缩力和增加心抟出量。例如，2023 年 6 月，英国製药公司 Hikma Pharmaceuticals plc 推出了 250 mg/20 mL管瓶多巴酚丁胺注射液 USP。这种注射液为因心臟收缩力下降而患有心肌梗塞的成年人提供短期强心作用，这种情况通常发生在心臟病或心血管手术后。多巴酚丁胺会刺激 β1 受体，在 1-2 分钟内增加心肌收缩力和心抟出量。注射剂经由静脉注射，通常在医院的严格医疗监督下使用。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球心血管因素的 PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素、限制因素）
  • 最终用途产业分析
  • 全球强心剂市场：成长率分析
  • 全球强心剂市场表现：规模与成长，2019-2024
  • 全球强心剂市场预测：2024-2029 年及 2034 年规模与成长
  • 全球强心剂总目标市场（TAM）

第六章市场区隔

  • 全球强心剂市场（按药物类型、性能和预测）2019-2024 年、2024-2029 年、2034 年
  • 洋地黄配糖体
  • 磷酸二酯酶抑制剂
  • 心臟保护剂
  • 拟交感神经药
  • 其他的
  • 全球强心剂市场（依给药途径、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 口服
  • 静脉
  • 其他的
  • 全球强心剂市场（依配方、效能和预测），2019-2024 年、2024-2029 年、2034 年
  • 锭剂
  • 解决方案
  • 其他的
  • 全球强心剂市场应用、绩效及预测（2019-2024、2024-2029、2034）
  • 心臟手术
  • 心房颤动
  • 心臟衰竭
  • 肺动脉高压
  • 其他的
  • 全球强心剂市场（依通路、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 医院药房
  • 零售药局
  • 网路药局
  • 全球强心剂市场：洋地黄配糖体细分类型、性能及预测（2019-2024、2024-2029、2034）
  • 地高辛
  • 洋地黄毒苷
  • 毛花苷C
  • 全球强心剂市场：磷酸二酯酶抑制剂按类型、性能和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 米力农
  • 依诺昔蒙
  • 氨力农
  • 全球心臟保护剂市场：按类型、性能和预测对心臟保护剂进行细分，2019-2024 年、2024-2029 年、2034 年
  • Coenzyme Q10
  • 右雷佐生
  • 曲美他嗪
  • 全球强心剂市场：拟交感神经药物按类型、性能和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 多巴酚丁胺
  • 多巴胺
  • 去甲肾上腺素
  • 全球强心剂市场：其他细分市场（按类型、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 左西孟旦
  • 奥美卡替尼
  • Cilostazol

第七章 区域和国家分析

  • 全球强心剂市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球强心剂市场（依国家、表现及预测）2019-2024、2024-2029、2034

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 心臟肌力药物市场：竞争格局
  • 心臟药物市场：公司简介
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Novartis AG
  • Eli Lilly and Company
  • Fresenius Kabi
  • Aurobindo Pharma Limited
  • Hikma Pharmaceuticals PLC
  • Alchem International Private Ltd
  • Farbe Firma Private Limited
  • Salius Pharma Pvt. Ltd.
  • Johnlee Pharmaceuticals Pvt. Ltd.
  • Healthy Life Pharma Pvt Ltd
  • Anwita Drugs
  • Varion Lifesciences
  • Deccan Nutraceuticals Pvt. Ltd

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年强心剂市场：提供新机会的国家
  • 2029年强心剂市场：细分市场带来新机会
  • 2029 年心臟肌力药物市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r35375

Cardiotonic agents are a group of drugs that enhance the strength and efficiency of heart muscle contractions, thereby improving the heart's ability to pump blood. These medications are primarily used to manage heart failure and certain arrhythmias by boosting cardiac output and enhancing blood circulation.

The main categories of cardiotonic agents include digitalis glycosides, phosphodiesterase inhibitors, cardioprotectants, sympathomimetic agents, and others. Digitalis glycosides are compounds extracted from the Digitalis plant, used to treat heart conditions by increasing contraction force and regulating heart rhythm. These drugs can be administered orally, intravenously, or via other methods, with common dosage forms including tablets and solutions. They are utilized in a variety of clinical scenarios such as cardiac surgeries, atrial fibrillation, heart failure, pulmonary hypertension, among others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The cardiotonic agents market research report is one of a series of new reports from The Business Research Company that provides cardiotonic agents market statistics, including cardiotonic agents industry global market size, regional shares, competitors with a cardiotonic agents market share, cardiotonic agents market segments, market trends and opportunities, and any further data you may need to thrive in the cardiotonic agents industry. This cardiotonic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiotonic agents market size has grown rapidly in recent years. It will grow from $2.78 billion in 2024 to $3.14 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth during the historic period can be attributed to the rising prevalence of heart failure, an expanding elderly population, an increasing incidence of coronary artery disease, greater adoption of sedentary lifestyles, and the growing burden of hypertension and diabetes.

The cardiotonic agents market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing cardiovascular mortality rates, a rise in clinical trials focused on enhanced cardiotonic formulations, expanding public-private collaborations in cardiovascular drug development, growing hospital admissions related to cardiac complications, and heightened demand for personalized cardiovascular medicine. Key trends during the forecast period include the development of peptide-based cardiotonic agents, creation of dual-mechanism drugs, integration of pharmacogenomics, innovation in injectable depot formulations, and advancement of combination therapies.

The increasing prevalence of cardiovascular diseases is expected to drive growth in the cardiotonic agents market in the coming years. Cardiovascular diseases (CVDs) include a group of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, arrhythmias, and stroke. This rise is largely attributed to unhealthy diets rich in saturated fats, trans fats, salt, and added sugars, which contribute to obesity, high blood pressure, and elevated cholesterol levels. Cardiotonic agents work by enhancing the heart muscle's efficiency and contraction strength, thereby supporting improved blood circulation and alleviating symptoms in various cardiovascular conditions. For example, in December 2023, the Australian Institute of Health and Welfare, an Australian government agency, reported that doctor-certified deaths due to coronary heart disease (CHD) increased from 14,100 in 2021 to 14,900 in 2022. Consequently, the rising prevalence of cardiovascular diseases is fueling the growth of the cardiotonic agents market.

Leading companies in the cardiotonic agents market are developing innovative products, including short-term inotropic drugs, aimed at improving cardiac performance in acute heart failure and cardiogenic shock. Short-term inotropic drugs are used to temporarily increase the heart's contractility, which enhances cardiac output. For instance, in June 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Dobutamine Injection, USP, in a 250 mg/20 mL vial. This injection provides short-term inotropic support for adults suffering from cardiac decompensation due to reduced heart contractility, often caused by heart disease or following cardiac surgery. Dobutamine stimulates beta-1 receptors to boost heart muscle contractility and cardiac output with a rapid onset of 1 to 2 minutes. The injection is administered intravenously and is typically used in hospital settings under close medical supervision.

In April 2023, SK Capital Partners LP, a US-based capital market company, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed sum. This acquisition aims to accelerate Apotex's growth and innovation by leveraging SK Capital's expertise to expand global access to affordable, high-quality pharmaceuticals. Apotex Pharmaceutical Holdings Inc., based in Canada, manufactures a cardiotonic agent marketed under the brand name Apo-Digoxin.

Major players in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, and Deccan Nutraceuticals Pvt. Ltd.

North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiotonic agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cardiotonic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiotonic agents market consists of sales of digoxin, milrinone, dobutamine, levosimendan, and amrinone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiotonic Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cardiotonic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiotonic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiotonic agents market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Type: Digitalis Glycosides; Phosphodiesterase Inhibitors; Cardioprotectants; Sympathomimetic Agents; Other Drug Types
  • 2) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
  • 3) By Dosage Form: Tablet; Solution; Other Dosage Forms
  • 4) By Application: Cardiac Surgical Procedures; Atrial Fibrillation; Heart Failure; Pulmonary Hypertension; Other Applications
  • 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By Digitalis Glycoside: Digoxin; Digitoxin; Lanatoside C
  • 2) By Phosphodiesterase Inhibitors: Milrinone; Enoximone; Amrinone
  • 3) By Cardioprotectants: Coenzyme Q10; Dexrazoxane; Trimetazidine
  • 4) By Sympathomimetic Agents: Dobutamine; Dopamine; Norepinephrine
  • 5) By Other Drug Types: Levosimendan; Omecamtiv Mecarbil; Cilostazol
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cardiotonic Agents Market Characteristics

3. Cardiotonic Agents Market Trends And Strategies

4. Cardiotonic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cardiotonic Agents Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cardiotonic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cardiotonic Agents Market Growth Rate Analysis
  • 5.4. Global Cardiotonic Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cardiotonic Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cardiotonic Agents Total Addressable Market (TAM)

6. Cardiotonic Agents Market Segmentation

  • 6.1. Global Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Digitalis Glycosides
  • Phosphodiesterase Inhibitors
  • Cardioprotectants
  • Sympathomimetic Agents
  • Other Drug Types
  • 6.2. Global Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Intravenous
  • Other Route Of Administrations
  • 6.3. Global Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tablet
  • Solution
  • Other Dosage Forms
  • 6.4. Global Cardiotonic Agents Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cardiac Surgical Procedures
  • Atrial Fibrillation
  • Heart Failure
  • Pulmonary Hypertension
  • Other Applications
  • 6.5. Global Cardiotonic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.6. Global Cardiotonic Agents Market, Sub-Segmentation Of Digitalis Glycosides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Digoxin
  • Digitoxin
  • Lanatoside C
  • 6.7. Global Cardiotonic Agents Market, Sub-Segmentation Of Phosphodiesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Milrinone
  • Enoximone
  • Amrinone
  • 6.8. Global Cardiotonic Agents Market, Sub-Segmentation Of Cardioprotectants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Coenzyme Q10
  • Dexrazoxane
  • Trimetazidine
  • 6.9. Global Cardiotonic Agents Market, Sub-Segmentation Of Sympathomimetic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Dobutamine
  • Dopamine
  • Norepinephrine
  • 6.10. Global Cardiotonic Agents Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Levosimendan
  • Omecamtiv Mecarbil
  • Cilostazol

7. Cardiotonic Agents Market Regional And Country Analysis

  • 7.1. Global Cardiotonic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cardiotonic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cardiotonic Agents Market

  • 8.1. Asia-Pacific Cardiotonic Agents Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cardiotonic Agents Market

  • 9.1. China Cardiotonic Agents Market Overview
  • 9.2. China Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cardiotonic Agents Market

  • 10.1. India Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cardiotonic Agents Market

  • 11.1. Japan Cardiotonic Agents Market Overview
  • 11.2. Japan Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cardiotonic Agents Market

  • 12.1. Australia Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cardiotonic Agents Market

  • 13.1. Indonesia Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cardiotonic Agents Market

  • 14.1. South Korea Cardiotonic Agents Market Overview
  • 14.2. South Korea Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cardiotonic Agents Market

  • 15.1. Western Europe Cardiotonic Agents Market Overview
  • 15.2. Western Europe Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cardiotonic Agents Market

  • 16.1. UK Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cardiotonic Agents Market

  • 17.1. Germany Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cardiotonic Agents Market

  • 18.1. France Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cardiotonic Agents Market

  • 19.1. Italy Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cardiotonic Agents Market

  • 20.1. Spain Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cardiotonic Agents Market

  • 21.1. Eastern Europe Cardiotonic Agents Market Overview
  • 21.2. Eastern Europe Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cardiotonic Agents Market

  • 22.1. Russia Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cardiotonic Agents Market

  • 23.1. North America Cardiotonic Agents Market Overview
  • 23.2. North America Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cardiotonic Agents Market

  • 24.1. USA Cardiotonic Agents Market Overview
  • 24.2. USA Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cardiotonic Agents Market

  • 25.1. Canada Cardiotonic Agents Market Overview
  • 25.2. Canada Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cardiotonic Agents Market

  • 26.1. South America Cardiotonic Agents Market Overview
  • 26.2. South America Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cardiotonic Agents Market

  • 27.1. Brazil Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cardiotonic Agents Market

  • 28.1. Middle East Cardiotonic Agents Market Overview
  • 28.2. Middle East Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cardiotonic Agents Market

  • 29.1. Africa Cardiotonic Agents Market Overview
  • 29.2. Africa Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cardiotonic Agents Market Competitive Landscape And Company Profiles

  • 30.1. Cardiotonic Agents Market Competitive Landscape
  • 30.2. Cardiotonic Agents Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Cardiotonic Agents Market Other Major And Innovative Companies

  • 31.1. Bristol-Myers Squibb Company
  • 31.2. AstraZeneca plc
  • 31.3. Novartis AG
  • 31.4. Eli Lilly and Company
  • 31.5. Fresenius Kabi
  • 31.6. Aurobindo Pharma Limited
  • 31.7. Hikma Pharmaceuticals PLC
  • 31.8. Alchem International Private Ltd
  • 31.9. Farbe Firma Private Limited
  • 31.10. Salius Pharma Pvt. Ltd.
  • 31.11. Johnlee Pharmaceuticals Pvt. Ltd.
  • 31.12. Healthy Life Pharma Pvt Ltd
  • 31.13. Anwita Drugs
  • 31.14. Varion Lifesciences
  • 31.15. Deccan Nutraceuticals Pvt. Ltd

32. Global Cardiotonic Agents Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cardiotonic Agents Market

34. Recent Developments In The Cardiotonic Agents Market

35. Cardiotonic Agents Market High Potential Countries, Segments and Strategies

  • 35.1 Cardiotonic Agents Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Cardiotonic Agents Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Cardiotonic Agents Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer